211 related articles for article (PubMed ID: 7905286)
1. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
[TBL] [Abstract][Full Text] [Related]
2. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.
Porgador A; Bannerji R; Watanabe Y; Feldman M; Gilboa E; Eisenbach L
J Immunol; 1993 Feb; 150(4):1458-70. PubMed ID: 8432988
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
Porgador A; Tzehoval E; Katz A; Vadai E; Revel M; Feldman M; Eisenbach L
Cancer Res; 1992 Jul; 52(13):3679-86. PubMed ID: 1617640
[TBL] [Abstract][Full Text] [Related]
6. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
7. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
10. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
11. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
[TBL] [Abstract][Full Text] [Related]
16. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
17. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
